Previous 10 | Next 10 |
Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing Trading on Nasdaq Capital Market is expected to begin on December 30, 2020 LAKE FOREST, Ill., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Asse...
Assertio (ASRT) announces a comprehensive restructuring plan designed to further reduce its cost base and right size its organization.The plan to reduce total annual cost base by ~$45M, after giving effect to one-time restructuring costs.These reductions are in addition to the previously...
LAKE FOREST, Ill., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced a comprehensive restructuring plan designed to further reduce its cost base and right size its organization. “To...
LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief executive officer and director, Todd Smith will present...
Assertio Holdings, Inc. (ASRT) Q3 2020 Earnings Conference Call November 06, 2020 08:30 AM ET Company Participants Lee Roth - Burns McClellan Todd Smith - President, CEO and Director Dan Peisert - Chief Financial Officer Mark Strobeck - Chief Operating Officer Conference Call Participants Sco...
Assertio Therapeutics (ASRT): Q3 GAAP EPS of -$0.09 misses by $0.05.Revenue of $34.57M (-37.3% Y/Y) beats by $2.07M.Press Release For further details see: Assertio Therapeutics EPS misses by $0.05, beats on revenue
Reported Net Product Sales of $34.3 Million Non-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020 Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effe...
LAKE FOREST, Ill., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third quarter 2020 financial results will be released on Friday, Novembe...
Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP declined by 1.2% net during the first nine months of 2020, outpacing the...
LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will present at and participate in investor meetings at the Cantor Vi...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...